BPTS - Biophytis launches OBA Phase 2 Clinical Study in Obesity and Reports 2023 Financial Results

2024-04-09 07:51:04 ET

DENVER, Colo., Apr 09, 2024 ( 247marketnews.com )- Biophytis SA (NASDAQ: BPTS ) reported that it is launching a new clinical development program named OBA, with BIO101 (20-hydroxyecdysone) as a potential treatment for obesity in combination with GLP-1 receptor agonists, and published its 2023 financial results.

Stanislas Veillet, CEO of Biophytis, stated: “We believe BIO101 (20-hydroxyecdysone) has the potential to be the molecule of choice for preserving muscle function in patients suffering from obesity who are treated with GLP-1 RAs. Our drug candidate,subject to regulatory approvals, could contribute to meeting crucial medical challenges, while positioning Biophytis in a large market with incredibly high growth potential. We believe that our leadership in developing drugs for muscular diseases and promising results obtained in obesity will be a strong accelerator of the OBA clinical plan.”

“In 2023, despite a particularly difficult financial environment for the biotech sector, we succeeded in pursuing the development of our clinical programmes, while securing the company’s financing until early 2025,” said Veillet. “We were able to confirm the therapeutic value of BIO101 (20-hydroxyecdysone), our lead drug candidate, in the treatment of patients suffering from severe forms of COVID-19, opening the door to wider use in viral Severe Acute Respiratory Infections (SARI). We have also obtained authorization to initiate a phase 3 SARA-31 trial in the United States and Belgium in sarcopenia, a disease that is still poorly understood but very common among the elderly and currently untreated. We are actively seeking global or regional pharmaceutical company partners to co-finance the phase 3 studies required to file a marketing authorization and to market BIO101 (20-hydroxyecdysone) in these two indications.Finally, we are starting a new phase 2 clinical development programme in obesity to assess the efficacy of BIO101 (20-hydroxyecdysone) in maintaining muscle function in obese patients treated with GLP-1 receptor agonists. We believe we can position ourselves as a key player in this fast-growing market, which is expected to reach over $100 billion by 2030 according to Goldman Sachs.”

The post Biophytis launches OBA Phase 2 Clinical Study in Obesity and Reports 2023 Financial Results appeared first on 24/7 MarketNews .

For further details see: